News
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results was that the company missed Wall Street's revenue and earnings estimates.
We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Vertex ...
VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...
Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46 ...
Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.
One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...
CEO Reshma Kewalramani highlighted the company’s strong performance in Q1 2025, with $2.77 billion in revenue, representing a 3% year-over-year increase. Growth was driven by expanding patient reach ...
Zacks Investment Research on MSN22h
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View TightenedVertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback